Resolve: Methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis
Identifieur interne : 003012 ( Main/Exploration ); précédent : 003011; suivant : 003013Resolve: Methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis
Auteurs : Robert F. Willkens [États-Unis]Source :
- Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 1990.
English descriptors
- Teeft :
- American college, Antirheumatic, Antirheumatic drugs, Arch intern, Arthritis, Arthritis rheum, Clinical professor, Clinical trial, Disease progression, Erosive disease, Gold therapy, Gold treatment, Grune stratton, Kremer, Liver biopsies, Liver histology, Marcel dekker, Methotrexate, Methotrexate therapy, Nsaid, Oliver wendell holmes, Primary goal, Progression, Prospective study, Pulmonary disease, Pulse methotrexate therapy, Radiological, Radiological progression, Rheum, Rheumatic disease, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Successful treatment, Toxicity, Willkens.
Abstract
Abstract: This article, in favor of the resolution that methotrexate (MTX) is the drug of choice after nonsteroidal antiinflammatory treatment, develops the following four points. MTX is an effective treatment of rheumatoid arthritis. MTX is easy to administer and to monitor for effectiveness and safety. MTX has demonstrated a therapeutic to toxic ratio that exceeds that of other second-line antirheumatic drugs. MTX has the potential to impair disease progression.
Url:
DOI: 10.1016/0049-0172(90)90020-G
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000782
- to stream Istex, to step Curation: 000782
- to stream Istex, to step Checkpoint: 001D82
- to stream Main, to step Merge: 003081
- to stream Main, to step Curation: 003012
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Resolve: Methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis</title><author><name sortKey="Willkens, Robert F" sort="Willkens, Robert F" uniqKey="Willkens R" first="Robert F." last="Willkens">Robert F. Willkens</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:33A8414F3A5E685FB8AAEF87BC0E87B2818C021B</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/0049-0172(90)90020-G</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-9BG367SX-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000782</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000782</idno><idno type="wicri:Area/Istex/Curation">000782</idno><idno type="wicri:Area/Istex/Checkpoint">001D82</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D82</idno><idno type="wicri:doubleKey">0049-0172:1990:Willkens R:resolve:methotrexate:is</idno><idno type="wicri:Area/Main/Merge">003081</idno><idno type="wicri:Area/Main/Curation">003012</idno><idno type="wicri:Area/Main/Exploration">003012</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Resolve: Methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis</title><author><name sortKey="Willkens, Robert F" sort="Willkens, Robert F" uniqKey="Willkens R" first="Robert F." last="Willkens">Robert F. Willkens</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harborview Medical Center, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="ISSN">0049-0172</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="76">76</biblScope><biblScope unit="page" to="80">80</biblScope></imprint><idno type="ISSN">0049-0172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0049-0172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>American college</term><term>Antirheumatic</term><term>Antirheumatic drugs</term><term>Arch intern</term><term>Arthritis</term><term>Arthritis rheum</term><term>Clinical professor</term><term>Clinical trial</term><term>Disease progression</term><term>Erosive disease</term><term>Gold therapy</term><term>Gold treatment</term><term>Grune stratton</term><term>Kremer</term><term>Liver biopsies</term><term>Liver histology</term><term>Marcel dekker</term><term>Methotrexate</term><term>Methotrexate therapy</term><term>Nsaid</term><term>Oliver wendell holmes</term><term>Primary goal</term><term>Progression</term><term>Prospective study</term><term>Pulmonary disease</term><term>Pulse methotrexate therapy</term><term>Radiological</term><term>Radiological progression</term><term>Rheum</term><term>Rheumatic disease</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatol</term><term>Successful treatment</term><term>Toxicity</term><term>Willkens</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: This article, in favor of the resolution that methotrexate (MTX) is the drug of choice after nonsteroidal antiinflammatory treatment, develops the following four points. MTX is an effective treatment of rheumatoid arthritis. MTX is easy to administer and to monitor for effectiveness and safety. MTX has demonstrated a therapeutic to toxic ratio that exceeds that of other second-line antirheumatic drugs. MTX has the potential to impair disease progression.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Washington (État)</li></region><settlement><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Willkens, Robert F" sort="Willkens, Robert F" uniqKey="Willkens R" first="Robert F." last="Willkens">Robert F. Willkens</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003012 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003012 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:33A8414F3A5E685FB8AAEF87BC0E87B2818C021B
|texte= Resolve: Methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |